{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:32:33Z","timestamp":1787959953382,"version":"build-2784847793"},"reference-count":81,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,3,11]],"date-time":"2015-03-11T00:00:00Z","timestamp":1426032000000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100014470","name":"Netherlands Heart Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014470","id-type":"DOI","asserted-by":"crossref"}]},{"name":"European Society of Cardiology Heart Failure Association Research Grant"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.jacc.2013.11.031","type":"journal-article","created":{"date-parts":[[2013,12,12]],"date-time":"2013-12-12T20:23:10Z","timestamp":1386879790000},"page":"853-871","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency"],"prefix":"10.1016","volume":"63","author":[{"given":"Kevin","family":"Damman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.H. Wilson","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Felker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lassus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Krum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2013.11.031_bib1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1093\/eurjhf\/hfs033","volume":"14","author":"McMurray","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib2","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib3","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.amjcard.2009.12.016","article-title":"Influence of renal function on the use of guideline-recommended therapies for patients with heart failure","volume":"105","author":"Heywood","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1007\/s11897-012-0122-8","article-title":"Pharmacologic management of chronic reno-cardiac syndrome","volume":"10","author":"Hawwa","year":"2013","journal-title":"Curr Heart Fail Rep"},{"key":"10.1016\/j.jacc.2013.11.031_bib5","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.jacc.2013.11.031_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1161\/CIRCHEARTFAILURE.111.966242","article-title":"Renal dysfunction in patients with heart failure with preserved versus reduced ejection fraction: impact of the new Chronic Kidney Disease-Epidemiology Collaboration Group formula","volume":"5","author":"McAlister","year":"2012","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib8","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.11.031_bib9","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib10","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","article-title":"Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS)","volume":"26","author":"Flather","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.11.031_bib11","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.cardfail.2010.01.001","article-title":"Renal function in outpatients with chronic heart failure","volume":"16","author":"Waldum","year":"2010","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib12","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib13","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0140-6736(09)61378-7","article-title":"Albuminuria in chronic heart failure: prevalence and prognostic importance","volume":"374","author":"Jackson","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.11.031_bib14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1161\/CIRCHEARTFAILURE.109.881805","article-title":"Prevalence and prognostic value of elevated urinary albumin excretion in patients with chronic heart failure: data from the GISSI-Heart Failure trial","volume":"3","author":"Masson","year":"2010","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib15","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.jacc.2008.07.051","article-title":"Cardiorenal syndrome","volume":"52","author":"Ronco","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib16","doi-asserted-by":"crossref","first-page":"40D","DOI":"10.1016\/0002-9149(90)90475-G","article-title":"Effects of enalapril and neuroendocrine activation on prognosis in severe congestive heart failure (follow-up of the CONSENSUS trial). CONSENSUS Trial Study Group","volume":"66","author":"Swedberg","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib17","doi-asserted-by":"crossref","first-page":"26D","DOI":"10.1016\/0002-9149(89)90414-1","article-title":"Enalapril for congestive heart failure","volume":"63","author":"Kjekshus","year":"1989","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib18","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ijcard.2011.12.056","article-title":"Effects of enalapril in systolic heart failure patients with and without chronic kidney disease: insights from the SOLVD Treatment trial","volume":"167","author":"Bowling","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/archinte.161.2.165","article-title":"Toleration of high doses of angiotensin-converting enzyme inhibitors in patients with chronic heart failure: results from the ATLAS trial. The Assessment of Treatment with Lisinopril and Survival","volume":"161","author":"Massie","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib20","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.1161\/01.CIR.0000149806.01354.BF","article-title":"Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study","volume":"110","author":"Tokmakova","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.031_bib21","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)","volume":"316","year":"1987","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib22","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(09)61913-9","article-title":"Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial","volume":"374","author":"Konstam","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.11.031_bib23","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.11.031_bib24","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","article-title":"Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study ELITE II","volume":"355","author":"Pitt","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.11.031_bib25","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.11.031_bib26","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib27","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1161\/CIRCULATIONAHA.109.853648","article-title":"Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure","volume":"120","author":"Anand","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.031_bib28","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.jacc.2007.07.067","article-title":"Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program","volume":"50","author":"Desai","year":"2007","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib29","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.11.031_bib30","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.jacc.2010.03.105","article-title":"Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial","volume":"56","author":"Cice","year":"2010","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib31","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib32","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/j.jacc.2012.07.048","article-title":"Influence of baseline and worsening renal function on efficacy of spironolactone in patients with severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study)","volume":"60","author":"Vardeny","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib33","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cardfail.2008.11.003","article-title":"The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CR\/XL Randomized Intervention Trial in Chronic HF (MERIT-HF)","volume":"15","author":"Ghali","year":"2009","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib35","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/eurjhf\/hfq038","article-title":"Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial","volume":"12","author":"Castagno","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib36","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/eurjhf\/hfp104","article-title":"Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial","volume":"11","author":"Cohen-Solal","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/CIRCHEARTFAILURE.109.932558","article-title":"Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials","volume":"4","author":"Wali","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib38","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib39","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group","volume":"336","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib40","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1097\/01.ASN.0000135121.81744.75","article-title":"Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial","volume":"15","author":"Shlipak","year":"2004","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2013.11.031_bib41","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.11.031_bib42","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.11.031_bib43","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","article-title":"Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study","volume":"314","author":"Cohn","year":"1986","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib44","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1161\/CIRCULATIONAHA.106.644013","article-title":"Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate\/hydralazine: consistency across subgroups in the African-American Heart Failure Trial","volume":"115","author":"Taylor","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.031_bib45","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1016\/j.jacc.2010.10.065","article-title":"Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function","volume":"57","author":"Damman","year":"2011","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib46","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(01)00903-2","article-title":"Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure","volume":"111","author":"Murray","year":"2001","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib47","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jacc.2012.12.043","article-title":"Dominance of furosemide for loop diuretic therapy in heart failure: time to revisit the alternatives?","volume":"61","author":"Bikdeli","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib48","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1388-9842(02)00122-8","article-title":"Torasemide in chronic heart failure: results of the TORIC study","volume":"4","author":"Cosin","year":"2002","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa043399","article-title":"Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure","volume":"352","author":"Bardy","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib50","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJM199612263352601","article-title":"Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia","volume":"335","author":"Moss","year":"1996","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib51","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa033088","article-title":"Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy","volume":"350","author":"Kadish","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib52","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa013474","article-title":"Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction","volume":"346","author":"Moss","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib53","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1056\/NEJM199711273372202","article-title":"A\u00a0comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias","volume":"337","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib54","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1161\/01.CIR.0000012350.99718.AD","article-title":"Primary prevention of sudden cardiac death in idiopathic dilated cardiomyopathy: the Cardiomyopathy Trial (CAT)","volume":"105","author":"Bansch","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.031_bib55","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/01.CIR.101.11.1297","article-title":"Canadian implantable defibrillator study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone","volume":"101","author":"Connolly","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.031_bib56","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/01.CIR.102.7.748","article-title":"Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: the Cardiac Arrest Study Hamburg (CASH)","volume":"102","author":"Kuck","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.031_bib57","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.amjcard.2006.03.025","article-title":"Relations among renal function, risk of sudden cardiac death, and benefit of the implanted cardiac defibrillator in patients with ischemic left ventricular dysfunction","volume":"98","author":"Goldenberg","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib58","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1056\/NEJMoa050496","article-title":"The effect of cardiac resynchronization on morbidity and mortality in heart failure","volume":"352","author":"Cleland","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib59","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa0906431","article-title":"Cardiac-resynchronization therapy for the prevention of heart-failure events","volume":"361","author":"Moss","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib60","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.hrthm.2010.09.005","article-title":"Relation between renal function and response to cardiac resynchronization therapy in Multicenter Automatic Defibrillator Implantation Trial\u2014Cardiac Resynchronization Therapy (MADIT-CRT)","volume":"7","author":"Goldenberg","year":"2010","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2013.11.031_bib61","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1009540","article-title":"Cardiac-resynchronization therapy for mild-to-moderate heart failure","volume":"363","author":"Tang","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib62","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.cardfail.2008.03.009","article-title":"Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate","volume":"14","author":"Boerrigter","year":"2008","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib63","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2215\/CJN.00750113","article-title":"Cardiac resynchronization therapy in CKD: a systematic review","volume":"8","author":"Garg","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2013.11.031_bib64","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa013168","article-title":"Cardiac resynchronization in chronic heart failure","volume":"346","author":"Abraham","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib65","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S0195-668X(02)00526-2","article-title":"Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: the CATS randomized trial","volume":"24","author":"Hillege","year":"2003","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.11.031_bib66","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1161\/CIRCHEARTFAILURE.111.963256","article-title":"Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction","volume":"4","author":"Testani","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib67","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1161\/CIRCULATIONAHA.111.028282","article-title":"Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study","volume":"125","author":"Rossignol","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.031_bib68","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0002-9149(92)91194-9","article-title":"Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial)","volume":"70","author":"Ljungman","year":"1992","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib69","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.cardfail.2007.04.008","article-title":"Worsening renal function and prognosis in heart failure: systematic review and meta-analysis","volume":"13","author":"Damman","year":"2007","journal-title":"J\u00a0Card Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib70","doi-asserted-by":"crossref","first-page":"917","DOI":"10.7326\/0003-4819-138-11-200306030-00013","article-title":"Pharmacotherapy for heart failure in patients with renal insufficiency","volume":"138","author":"Shlipak","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2013.11.031_bib71","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.11.031_bib72","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2013.11.031_bib73","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1053\/euhj.1997.0839","article-title":"Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison","volume":"19","year":"1998","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.11.031_bib74","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0002-8703(99)70009-8","article-title":"Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD)","volume":"138","author":"Knight","year":"1999","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2013.11.031_bib75","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.ejheart.2008.01.011","article-title":"Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance","volume":"10","author":"Metra","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2013.11.031_bib76","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of eplerenone in patients at high-risk for hyperkalemia and\/or worsening renal function: analyses of EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)","volume":"62","author":"Eschalier","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2013.11.031_bib77","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1471-2261-11-37","article-title":"Renal function at the time of a myocardial infarction maintains prognostic value for more than 10 years","volume":"11","author":"Kumler","year":"2011","journal-title":"BMC Cardiovasc Disord"},{"key":"10.1016\/j.jacc.2013.11.031_bib78","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1161\/CIRCULATIONAHA.105.580506","article-title":"Renal function as a predictor of outcome in a broad spectrum of patients with heart failure","volume":"113","author":"Hillege","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2013.11.031_bib79","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1053\/euhj.2002.3232","article-title":"Comparative effects of permanent biventricular and right-univentricular pacing in heart failure patients with chronic atrial fibrillation","volume":"23","author":"Leclercq","year":"2002","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2013.11.031_bib80","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1001\/jama.289.20.2685","article-title":"Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial","volume":"289","author":"Young","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2013.11.031_bib81","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1017\/S0266462312000037","article-title":"Bayesian meta-analysis on medical devices: application to implantable cardioverter defibrillators","volume":"28","author":"Youn","year":"2012","journal-title":"Int J Technol Assess Health Care"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713064255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109713064255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:07:26Z","timestamp":1760015246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109713064255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0735109713064255"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2013.11.031","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2013.11.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}